Akthelia Pharmaceuticals is a preclinical stage pharmaceutical company focused on enhancing and deploying the body's innate microbial defense mechanisms to combat debilitating diseases. Founded by four eminent professors, Akthelia's founders were pioneers in isolating and characterizing the host defense peptide LL-37, a significant breakthrough in humans. By strengthening innate gut barrier defenses, Akthelia's drug candidate effectively eliminates the need for prophylactic antibiotics, reducing the risk of serious adverse events, antimicrobial resistance, and microbiome dysbiosis.

Akthelia's innovative approach is supported by rigorous patent protection, and the company's intellectual property advisers, Mewburn Ellis, ensure the security of their unique actives. Located in Reykjavik, Iceland, Akthelia has secured funding through equity and grants, including investments from private pharma investors and support from NSA Ventures and RANNÍS. With their cutting-edge technology and experienced team, Akthelia Pharmaceuticals is at the forefront of developing groundbreaking therapeutics to address the urgent medical needs of patients worldwide